argenx SE (EBR:ARGX)
751.00
+23.00 (3.16%)
Aug 5, 2026, 4:05 PM CET
argenx SE Revenue
argenx SE had revenue of $1.54B USD in the quarter ending June 30, 2026, with 59.30% growth. This brings the company's revenue in the last twelve months to $5.33B, up 70.51% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$5.33B
Revenue Growth
+70.51%
P/S Ratio
9.79
Revenue / Employee
$2.86M
Employees
1,863
Market Cap
45.53B EUR
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 8.52B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 7.94M |
| Onward Medical | 5.41M |
| Oxurion NV | 555.00K |
| Celyad Oncology | 21.00K |
| Financière de Tubize | 13.26K |
| BioSenic | -2.39M |
argenx SE News
- 21 hours ago - Argenx resumed with a Buy at Guggenheim - TheFly
- 1 day ago - argenx announces Extraordinary General Meeting of Shareholders on September 17, 2026 - GlobeNewsWire
- 5 days ago - A portfolio manager says investors are looking overseas as Magnificent Seven worries grow. Here are the stocks and sectors he favors - CNBC
- 5 days ago - IBB, REGN, ARGX, ALNY: Large Outflows Detected at ETF - Nasdaq
- 7 days ago - Corning removed from ‘US 1 List’ at BofA - TheFly
- 7 days ago - Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX - Business Wire
- 7 days ago - ARGX Maintained by Wedbush -- Price Target Raised to $1050 - GuruFocus
- 8 days ago - First Tracks Biotherapeutics price target raised to $60 from $30 at Wedbush - TheFly